Prenetics Global Limited
Get $10 bonus on your first $100 deposit for PRE
Get $10 bonus on your first $100 deposit for PRE
Prenetics Global Limited (PRE) Stock Competitors & Peer Comparison
See (PRE) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PRE | $19.68 | +0.56% | 276.6M | -5.19 | -$3.79 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.71% |
| TMO | $491.46 | -0.62% | 182.6B | 27.69 | $17.75 | +0.36% |
| DHR | $191.12 | +0.17% | 135.1B | 38.00 | $5.03 | +0.71% |
| IDXX | $569.55 | +0.87% | 45.3B | 43.48 | $13.10 | N/A |
| A | $115.48 | +0.82% | 32.7B | 25.49 | $4.53 | +0.87% |
| NTRA | $207.98 | +2.35% | 29.5B | -136.83 | -$1.52 | N/A |
| IQV | $173.26 | +0.50% | 29.4B | 22.10 | $7.84 | N/A |
| MTD | $1,259.94 | -1.11% | 25.6B | 29.97 | $42.04 | N/A |
| LH | $273.72 | +0.36% | 22.7B | 26.17 | $10.46 | +1.05% |
Stock Comparison
PRE vs DHR-PB Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, PRE is priced at $19.68, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, PRE's ROE is -0.36%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, PRE is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check DHR-PB's competition here
PRE vs TMO Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, TMO has a market cap of 182.6B. Regarding current trading prices, PRE is priced at $19.68, while TMO trades at $491.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas TMO's P/E ratio is 27.69. In terms of profitability, PRE's ROE is -0.36%, compared to TMO's ROE of +0.13%. Regarding short-term risk, PRE is more volatile compared to TMO. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check TMO's competition here
PRE vs DHR Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, DHR has a market cap of 135.1B. Regarding current trading prices, PRE is priced at $19.68, while DHR trades at $191.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas DHR's P/E ratio is 38.00. In terms of profitability, PRE's ROE is -0.36%, compared to DHR's ROE of +0.07%. Regarding short-term risk, PRE is more volatile compared to DHR. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check DHR's competition here
PRE vs IDXX Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, IDXX has a market cap of 45.3B. Regarding current trading prices, PRE is priced at $19.68, while IDXX trades at $569.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas IDXX's P/E ratio is 43.48. In terms of profitability, PRE's ROE is -0.36%, compared to IDXX's ROE of +0.70%. Regarding short-term risk, PRE is more volatile compared to IDXX. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check IDXX's competition here
PRE vs A Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, A has a market cap of 32.7B. Regarding current trading prices, PRE is priced at $19.68, while A trades at $115.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas A's P/E ratio is 25.49. In terms of profitability, PRE's ROE is -0.36%, compared to A's ROE of +0.20%. Regarding short-term risk, PRE is more volatile compared to A. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check A's competition here
PRE vs NTRA Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, NTRA has a market cap of 29.5B. Regarding current trading prices, PRE is priced at $19.68, while NTRA trades at $207.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas NTRA's P/E ratio is -136.83. In terms of profitability, PRE's ROE is -0.36%, compared to NTRA's ROE of -0.15%. Regarding short-term risk, PRE is more volatile compared to NTRA. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check NTRA's competition here
PRE vs IQV Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, IQV has a market cap of 29.4B. Regarding current trading prices, PRE is priced at $19.68, while IQV trades at $173.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas IQV's P/E ratio is 22.10. In terms of profitability, PRE's ROE is -0.36%, compared to IQV's ROE of +0.22%. Regarding short-term risk, PRE is more volatile compared to IQV. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check IQV's competition here
PRE vs MTD Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, MTD has a market cap of 25.6B. Regarding current trading prices, PRE is priced at $19.68, while MTD trades at $1,259.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas MTD's P/E ratio is 29.97. In terms of profitability, PRE's ROE is -0.36%, compared to MTD's ROE of -4.87%. Regarding short-term risk, PRE is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check MTD's competition here
PRE vs LH Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, LH has a market cap of 22.7B. Regarding current trading prices, PRE is priced at $19.68, while LH trades at $273.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas LH's P/E ratio is 26.17. In terms of profitability, PRE's ROE is -0.36%, compared to LH's ROE of +0.10%. Regarding short-term risk, PRE is more volatile compared to LH. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check LH's competition here
PRE vs DGX Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, DGX has a market cap of 22B. Regarding current trading prices, PRE is priced at $19.68, while DGX trades at $198.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas DGX's P/E ratio is 22.63. In terms of profitability, PRE's ROE is -0.36%, compared to DGX's ROE of +0.14%. Regarding short-term risk, PRE is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check DGX's competition here
PRE vs EXAS Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, PRE is priced at $19.68, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas EXAS's P/E ratio is -95.37. In terms of profitability, PRE's ROE is -0.36%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, PRE is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check EXAS's competition here
PRE vs ILMN Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, ILMN has a market cap of 19.5B. Regarding current trading prices, PRE is priced at $19.68, while ILMN trades at $127.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas ILMN's P/E ratio is 23.37. In terms of profitability, PRE's ROE is -0.36%, compared to ILMN's ROE of +0.35%. Regarding short-term risk, PRE is more volatile compared to ILMN. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check ILMN's competition here
PRE vs WAT Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, WAT has a market cap of 18.1B. Regarding current trading prices, PRE is priced at $19.68, while WAT trades at $304.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas WAT's P/E ratio is 28.25. In terms of profitability, PRE's ROE is -0.36%, compared to WAT's ROE of +0.29%. Regarding short-term risk, PRE is more volatile compared to WAT. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check WAT's competition here
PRE vs PKI Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, PRE is priced at $19.68, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas PKI's P/E ratio is 41.45. In terms of profitability, PRE's ROE is -0.36%, compared to PKI's ROE of +0.03%. Regarding short-term risk, PRE is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check PKI's competition here
PRE vs MEDP Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, MEDP has a market cap of 14.1B. Regarding current trading prices, PRE is priced at $19.68, while MEDP trades at $498.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas MEDP's P/E ratio is 32.66. In terms of profitability, PRE's ROE is -0.36%, compared to MEDP's ROE of +1.19%. Regarding short-term risk, PRE is more volatile compared to MEDP. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check MEDP's competition here
PRE vs GH Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, GH has a market cap of 12.3B. Regarding current trading prices, PRE is priced at $19.68, while GH trades at $93.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas GH's P/E ratio is -28.26. In terms of profitability, PRE's ROE is -0.36%, compared to GH's ROE of +1.65%. Regarding short-term risk, PRE is less volatile compared to GH. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check GH's competition here
PRE vs RVTY Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, RVTY has a market cap of 9.9B. Regarding current trading prices, PRE is priced at $19.68, while RVTY trades at $88.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas RVTY's P/E ratio is 43.17. In terms of profitability, PRE's ROE is -0.36%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, PRE is more volatile compared to RVTY. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check RVTY's competition here
PRE vs ICLR Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, ICLR has a market cap of 8.7B. Regarding current trading prices, PRE is priced at $19.68, while ICLR trades at $114.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas ICLR's P/E ratio is 15.39. In terms of profitability, PRE's ROE is -0.36%, compared to ICLR's ROE of +0.06%. Regarding short-term risk, PRE is more volatile compared to ICLR. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check ICLR's competition here
PRE vs CRL Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, CRL has a market cap of 8.6B. Regarding current trading prices, PRE is priced at $19.68, while CRL trades at $173.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas CRL's P/E ratio is -59.96. In terms of profitability, PRE's ROE is -0.36%, compared to CRL's ROE of -0.04%. Regarding short-term risk, PRE is more volatile compared to CRL. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check CRL's competition here
PRE vs QGEN Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, QGEN has a market cap of 8.5B. Regarding current trading prices, PRE is priced at $19.68, while QGEN trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas QGEN's P/E ratio is 20.11. In terms of profitability, PRE's ROE is -0.36%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, PRE is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check QGEN's competition here
PRE vs SYNH Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, PRE is priced at $19.68, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas SYNH's P/E ratio is 61.40. In terms of profitability, PRE's ROE is -0.36%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, PRE is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check SYNH's competition here
PRE vs SHC Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, SHC has a market cap of 4.3B. Regarding current trading prices, PRE is priced at $19.68, while SHC trades at $14.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas SHC's P/E ratio is 55.41. In terms of profitability, PRE's ROE is -0.36%, compared to SHC's ROE of +0.15%. Regarding short-term risk, PRE is more volatile compared to SHC. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check SHC's competition here
PRE vs RDNT Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, RDNT has a market cap of 4.3B. Regarding current trading prices, PRE is priced at $19.68, while RDNT trades at $54.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas RDNT's P/E ratio is -219.16. In terms of profitability, PRE's ROE is -0.36%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, PRE is more volatile compared to RDNT. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check RDNT's competition here
PRE vs BLLN Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, BLLN has a market cap of 3.6B. Regarding current trading prices, PRE is priced at $19.68, while BLLN trades at $79.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas BLLN's P/E ratio is 566.86. In terms of profitability, PRE's ROE is -0.36%, compared to BLLN's ROE of +0.01%. Regarding short-term risk, PRE is less volatile compared to BLLN. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check BLLN's competition here
PRE vs OLK Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, PRE is priced at $19.68, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas OLK's P/E ratio is -96.59. In terms of profitability, PRE's ROE is -0.36%, compared to OLK's ROE of -0.07%. Regarding short-term risk, PRE is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check OLK's competition here
PRE vs TWST Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, TWST has a market cap of 3.1B. Regarding current trading prices, PRE is priced at $19.68, while TWST trades at $50.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas TWST's P/E ratio is -39.54. In terms of profitability, PRE's ROE is -0.36%, compared to TWST's ROE of -0.17%. Regarding short-term risk, PRE is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check TWST's competition here
PRE vs GRAL Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, GRAL has a market cap of 2.3B. Regarding current trading prices, PRE is priced at $19.68, while GRAL trades at $54.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas GRAL's P/E ratio is -4.95. In terms of profitability, PRE's ROE is -0.36%, compared to GRAL's ROE of -0.17%. Regarding short-term risk, PRE is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check GRAL's competition here
PRE vs NEOG Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, NEOG has a market cap of 2B. Regarding current trading prices, PRE is priced at $19.68, while NEOG trades at $9.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas NEOG's P/E ratio is -3.38. In terms of profitability, PRE's ROE is -0.36%, compared to NEOG's ROE of -0.27%. Regarding short-term risk, PRE is more volatile compared to NEOG. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check NEOG's competition here
PRE vs CDNA Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, CDNA has a market cap of 941.7M. Regarding current trading prices, PRE is priced at $19.68, while CDNA trades at $18.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas CDNA's P/E ratio is -45.77. In terms of profitability, PRE's ROE is -0.36%, compared to CDNA's ROE of -0.06%. Regarding short-term risk, PRE is more volatile compared to CDNA. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check CDNA's competition here
PRE vs OPK Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, OPK has a market cap of 875.2M. Regarding current trading prices, PRE is priced at $19.68, while OPK trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas OPK's P/E ratio is -3.80. In terms of profitability, PRE's ROE is -0.36%, compared to OPK's ROE of -0.17%. Regarding short-term risk, PRE is more volatile compared to OPK. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check OPK's competition here
PRE vs CSTL Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, CSTL has a market cap of 738.5M. Regarding current trading prices, PRE is priced at $19.68, while CSTL trades at $24.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas CSTL's P/E ratio is -29.93. In terms of profitability, PRE's ROE is -0.36%, compared to CSTL's ROE of -0.05%. Regarding short-term risk, PRE is more volatile compared to CSTL. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check CSTL's competition here
PRE vs PSNL Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, PSNL has a market cap of 584.3M. Regarding current trading prices, PRE is priced at $19.68, while PSNL trades at $6.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas PSNL's P/E ratio is -7.23. In terms of profitability, PRE's ROE is -0.36%, compared to PSNL's ROE of -0.39%. Regarding short-term risk, PRE is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check PSNL's competition here
PRE vs GRALV Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, PRE is priced at $19.68, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas GRALV's P/E ratio is N/A. In terms of profitability, PRE's ROE is -0.36%, compared to GRALV's ROE of N/A. Regarding short-term risk, PRE is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check GRALV's competition here
PRE vs FLGT Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, FLGT has a market cap of 525.3M. Regarding current trading prices, PRE is priced at $19.68, while FLGT trades at $16.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas FLGT's P/E ratio is -8.54. In terms of profitability, PRE's ROE is -0.36%, compared to FLGT's ROE of -0.05%. Regarding short-term risk, PRE is more volatile compared to FLGT. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check FLGT's competition here
PRE vs ACRS Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, ACRS has a market cap of 506.5M. Regarding current trading prices, PRE is priced at $19.68, while ACRS trades at $4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas ACRS's P/E ratio is -7.92. In terms of profitability, PRE's ROE is -0.36%, compared to ACRS's ROE of -0.52%. Regarding short-term risk, PRE is more volatile compared to ACRS. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check ACRS's competition here
PRE vs MYGN Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, MYGN has a market cap of 444.2M. Regarding current trading prices, PRE is priced at $19.68, while MYGN trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas MYGN's P/E ratio is -1.20. In terms of profitability, PRE's ROE is -0.36%, compared to MYGN's ROE of -0.80%. Regarding short-term risk, PRE is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check MYGN's competition here
PRE vs CO Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, PRE is priced at $19.68, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas CO's P/E ratio is 5.06. In terms of profitability, PRE's ROE is -0.36%, compared to CO's ROE of +0.11%. Regarding short-term risk, PRE is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check CO's competition here
PRE vs FLDM Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, PRE is priced at $19.68, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas FLDM's P/E ratio is -4.74. In terms of profitability, PRE's ROE is -0.36%, compared to FLDM's ROE of -0.18%. Regarding short-term risk, PRE is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check FLDM's competition here
PRE vs ATLN Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, ATLN has a market cap of 278.3M. Regarding current trading prices, PRE is priced at $19.68, while ATLN trades at $3.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas ATLN's P/E ratio is -1.57. In terms of profitability, PRE's ROE is -0.36%, compared to ATLN's ROE of +6.06%. Regarding short-term risk, PRE is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check ATLN's competition here
PRE vs OPGN Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, OPGN has a market cap of 242.7M. Regarding current trading prices, PRE is priced at $19.68, while OPGN trades at $23.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas OPGN's P/E ratio is 132.83. In terms of profitability, PRE's ROE is -0.36%, compared to OPGN's ROE of +0.78%. Regarding short-term risk, PRE is more volatile compared to OPGN. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check OPGN's competition here
PRE vs NEO Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, NEO has a market cap of 207.7M. Regarding current trading prices, PRE is priced at $19.68, while NEO trades at $8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas NEO's P/E ratio is -9.52. In terms of profitability, PRE's ROE is -0.36%, compared to NEO's ROE of -0.13%. Regarding short-term risk, PRE is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check NEO's competition here
PRE vs GTH Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, PRE is priced at $19.68, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas GTH's P/E ratio is -1.11. In terms of profitability, PRE's ROE is -0.36%, compared to GTH's ROE of -1.01%. Regarding short-term risk, PRE is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check GTH's competition here
PRE vs BDSX Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, BDSX has a market cap of 113.8M. Regarding current trading prices, PRE is priced at $19.68, while BDSX trades at $15.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas BDSX's P/E ratio is -3.23. In terms of profitability, PRE's ROE is -0.36%, compared to BDSX's ROE of -17.61%. Regarding short-term risk, PRE is more volatile compared to BDSX. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check BDSX's competition here
PRE vs GENE Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, PRE is priced at $19.68, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas GENE's P/E ratio is -38.25. In terms of profitability, PRE's ROE is -0.36%, compared to GENE's ROE of -1.85%. Regarding short-term risk, PRE is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check GENE's competition here
PRE vs MDXH Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, MDXH has a market cap of 110.9M. Regarding current trading prices, PRE is priced at $19.68, while MDXH trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas MDXH's P/E ratio is -3.22. In terms of profitability, PRE's ROE is -0.36%, compared to MDXH's ROE of +5.17%. Regarding short-term risk, PRE is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check MDXH's competition here
PRE vs STIM Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, STIM has a market cap of 105.3M. Regarding current trading prices, PRE is priced at $19.68, while STIM trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas STIM's P/E ratio is -2.58. In terms of profitability, PRE's ROE is -0.36%, compared to STIM's ROE of -1.39%. Regarding short-term risk, PRE is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check STIM's competition here
PRE vs SERA Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, SERA has a market cap of 76.7M. Regarding current trading prices, PRE is priced at $19.68, while SERA trades at $2.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas SERA's P/E ratio is -3.00. In terms of profitability, PRE's ROE is -0.36%, compared to SERA's ROE of -0.37%. Regarding short-term risk, PRE is more volatile compared to SERA. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check SERA's competition here
PRE vs XGN Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, XGN has a market cap of 73.6M. Regarding current trading prices, PRE is priced at $19.68, while XGN trades at $3.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas XGN's P/E ratio is -3.29. In terms of profitability, PRE's ROE is -0.36%, compared to XGN's ROE of -1.27%. Regarding short-term risk, PRE is more volatile compared to XGN. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check XGN's competition here
PRE vs DRIO Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, DRIO has a market cap of 61.3M. Regarding current trading prices, PRE is priced at $19.68, while DRIO trades at $8.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas DRIO's P/E ratio is -0.83. In terms of profitability, PRE's ROE is -0.36%, compared to DRIO's ROE of +0.88%. Regarding short-term risk, PRE is more volatile compared to DRIO. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check DRIO's competition here
PRE vs PRPO Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, PRPO has a market cap of 44.5M. Regarding current trading prices, PRE is priced at $19.68, while PRPO trades at $25.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas PRPO's P/E ratio is -110.43. In terms of profitability, PRE's ROE is -0.36%, compared to PRPO's ROE of -0.03%. Regarding short-term risk, PRE is less volatile compared to PRPO. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check PRPO's competition here
PRE vs STRR Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, STRR has a market cap of 36.1M. Regarding current trading prices, PRE is priced at $19.68, while STRR trades at $9.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas STRR's P/E ratio is -4.69. In terms of profitability, PRE's ROE is -0.36%, compared to STRR's ROE of -0.10%. Regarding short-term risk, PRE is less volatile compared to STRR. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check STRR's competition here
PRE vs STRRP Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, STRRP has a market cap of 32M. Regarding current trading prices, PRE is priced at $19.68, while STRRP trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas STRRP's P/E ratio is -5.01. In terms of profitability, PRE's ROE is -0.36%, compared to STRRP's ROE of -0.10%. Regarding short-term risk, PRE is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check STRRP's competition here
PRE vs AKU Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, PRE is priced at $19.68, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas AKU's P/E ratio is -0.13. In terms of profitability, PRE's ROE is -0.36%, compared to AKU's ROE of -5.32%. Regarding short-term risk, PRE is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check AKU's competition here
PRE vs BIAF Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, BIAF has a market cap of 17.6M. Regarding current trading prices, PRE is priced at $19.68, while BIAF trades at $3.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas BIAF's P/E ratio is -0.45. In terms of profitability, PRE's ROE is -0.36%, compared to BIAF's ROE of -3.85%. Regarding short-term risk, PRE is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check BIAF's competition here
PRE vs BNR Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, BNR has a market cap of 17.4M. Regarding current trading prices, PRE is priced at $19.68, while BNR trades at $16.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas BNR's P/E ratio is -21.89. In terms of profitability, PRE's ROE is -0.36%, compared to BNR's ROE of -0.10%. Regarding short-term risk, PRE is more volatile compared to BNR. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check BNR's competition here
PRE vs VNRX Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, VNRX has a market cap of 17.1M. Regarding current trading prices, PRE is priced at $19.68, while VNRX trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas VNRX's P/E ratio is -0.78. In terms of profitability, PRE's ROE is -0.36%, compared to VNRX's ROE of +0.72%. Regarding short-term risk, PRE is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check VNRX's competition here
PRE vs CEMI Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, PRE is priced at $19.68, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas CEMI's P/E ratio is -0.63. In terms of profitability, PRE's ROE is -0.36%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, PRE is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check CEMI's competition here
PRE vs ENZ Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, PRE is priced at $19.68, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas ENZ's P/E ratio is -2.24. In terms of profitability, PRE's ROE is -0.36%, compared to ENZ's ROE of -0.17%. Regarding short-term risk, PRE is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check ENZ's competition here
PRE vs PMD Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, PRE is priced at $19.68, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas PMD's P/E ratio is -5.24. In terms of profitability, PRE's ROE is -0.36%, compared to PMD's ROE of -0.32%. Regarding short-term risk, PRE is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check PMD's competition here
PRE vs ME Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, PRE is priced at $19.68, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas ME's P/E ratio is -0.03. In terms of profitability, PRE's ROE is -0.36%, compared to ME's ROE of -7.71%. Regarding short-term risk, PRE is more volatile compared to ME. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check ME's competition here
PRE vs MBAI Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, MBAI has a market cap of 10.6M. Regarding current trading prices, PRE is priced at $19.68, while MBAI trades at $1.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas MBAI's P/E ratio is -0.78. In terms of profitability, PRE's ROE is -0.36%, compared to MBAI's ROE of -2.26%. Regarding short-term risk, PRE is less volatile compared to MBAI. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check MBAI's competition here
PRE vs CHEK Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, CHEK has a market cap of 9.8M. Regarding current trading prices, PRE is priced at $19.68, while CHEK trades at $1.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas CHEK's P/E ratio is -0.39. In terms of profitability, PRE's ROE is -0.36%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, PRE is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check CHEK's competition here
PRE vs CNTG Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, PRE is priced at $19.68, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas CNTG's P/E ratio is -0.23. In terms of profitability, PRE's ROE is -0.36%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, PRE is more volatile compared to CNTG. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check CNTG's competition here
PRE vs NOTV Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, NOTV has a market cap of 9.2M. Regarding current trading prices, PRE is priced at $19.68, while NOTV trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas NOTV's P/E ratio is -0.14. In terms of profitability, PRE's ROE is -0.36%, compared to NOTV's ROE of -0.51%. Regarding short-term risk, PRE is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check NOTV's competition here
PRE vs APDN Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, PRE is priced at $19.68, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas APDN's P/E ratio is -0.10. In terms of profitability, PRE's ROE is -0.36%, compared to APDN's ROE of -8.97%. Regarding short-term risk, PRE is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check APDN's competition here
PRE vs TRIB Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, TRIB has a market cap of 6.3M. Regarding current trading prices, PRE is priced at $19.68, while TRIB trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas TRIB's P/E ratio is -0.38. In terms of profitability, PRE's ROE is -0.36%, compared to TRIB's ROE of +0.81%. Regarding short-term risk, PRE is more volatile compared to TRIB. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check TRIB's competition here
PRE vs QUCY Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, QUCY has a market cap of 5.7M. Regarding current trading prices, PRE is priced at $19.68, while QUCY trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas QUCY's P/E ratio is -0.02. In terms of profitability, PRE's ROE is -0.36%, compared to QUCY's ROE of -4.66%. Regarding short-term risk, PRE is more volatile compared to QUCY. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check QUCY's competition here
PRE vs NVTA Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, PRE is priced at $19.68, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas NVTA's P/E ratio is -0.00. In terms of profitability, PRE's ROE is -0.36%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, PRE is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check NVTA's competition here
PRE vs LMDX Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, PRE is priced at $19.68, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas LMDX's P/E ratio is -0.01. In terms of profitability, PRE's ROE is -0.36%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, PRE is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check LMDX's competition here
PRE vs LMDXW Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, PRE is priced at $19.68, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, PRE's ROE is -0.36%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, PRE is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check LMDXW's competition here
PRE vs ADVB Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, ADVB has a market cap of 4.9M. Regarding current trading prices, PRE is priced at $19.68, while ADVB trades at $4.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas ADVB's P/E ratio is 1.29. In terms of profitability, PRE's ROE is -0.36%, compared to ADVB's ROE of +1.01%. Regarding short-term risk, PRE is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check ADVB's competition here
PRE vs BGLC Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, BGLC has a market cap of 4M. Regarding current trading prices, PRE is priced at $19.68, while BGLC trades at $2.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas BGLC's P/E ratio is -1.73. In terms of profitability, PRE's ROE is -0.36%, compared to BGLC's ROE of -0.30%. Regarding short-term risk, PRE is more volatile compared to BGLC. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check BGLC's competition here
PRE vs BNGO Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, BNGO has a market cap of 3.9M. Regarding current trading prices, PRE is priced at $19.68, while BNGO trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas BNGO's P/E ratio is -0.25. In terms of profitability, PRE's ROE is -0.36%, compared to BNGO's ROE of -0.56%. Regarding short-term risk, PRE is more volatile compared to BNGO. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check BNGO's competition here
PRE vs NDRA Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, NDRA has a market cap of 3.5M. Regarding current trading prices, PRE is priced at $19.68, while NDRA trades at $4.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas NDRA's P/E ratio is 0.24. In terms of profitability, PRE's ROE is -0.36%, compared to NDRA's ROE of -4.97%. Regarding short-term risk, PRE is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check NDRA's competition here
PRE vs DMTK Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, PRE is priced at $19.68, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas DMTK's P/E ratio is -0.04. In terms of profitability, PRE's ROE is -0.36%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, PRE is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check DMTK's competition here
PRE vs MYNZ Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, MYNZ has a market cap of 2.9M. Regarding current trading prices, PRE is priced at $19.68, while MYNZ trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas MYNZ's P/E ratio is -0.13. In terms of profitability, PRE's ROE is -0.36%, compared to MYNZ's ROE of -10.25%. Regarding short-term risk, PRE is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check MYNZ's competition here
PRE vs SQL Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, PRE is priced at $19.68, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas SQL's P/E ratio is -0.40. In terms of profitability, PRE's ROE is -0.36%, compared to SQL's ROE of +9.82%. Regarding short-term risk, PRE is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check SQL's competition here
PRE vs AWH Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, PRE is priced at $19.68, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas AWH's P/E ratio is -0.09. In terms of profitability, PRE's ROE is -0.36%, compared to AWH's ROE of +3.65%. Regarding short-term risk, PRE is more volatile compared to AWH. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check AWH's competition here
PRE vs INBS Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, INBS has a market cap of 1.8M. Regarding current trading prices, PRE is priced at $19.68, while INBS trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas INBS's P/E ratio is -0.19. In terms of profitability, PRE's ROE is -0.36%, compared to INBS's ROE of -1.98%. Regarding short-term risk, PRE is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check INBS's competition here
PRE vs BIAFW Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, BIAFW has a market cap of 1.3M. Regarding current trading prices, PRE is priced at $19.68, while BIAFW trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas BIAFW's P/E ratio is N/A. In terms of profitability, PRE's ROE is -0.36%, compared to BIAFW's ROE of -3.85%. Regarding short-term risk, PRE is less volatile compared to BIAFW. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check BIAFW's competition here
PRE vs HTGM Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, PRE is priced at $19.68, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas HTGM's P/E ratio is -0.03. In terms of profitability, PRE's ROE is -0.36%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, PRE is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check HTGM's competition here
PRE vs ISPC Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, ISPC has a market cap of 789.8K. Regarding current trading prices, PRE is priced at $19.68, while ISPC trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas ISPC's P/E ratio is -0.06. In terms of profitability, PRE's ROE is -0.36%, compared to ISPC's ROE of -5.46%. Regarding short-term risk, PRE is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check ISPC's competition here
PRE vs BIOC Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, PRE is priced at $19.68, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas BIOC's P/E ratio is -0.01. In terms of profitability, PRE's ROE is -0.36%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, PRE is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check BIOC's competition here
PRE vs PRENW Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, PRENW has a market cap of 253K. Regarding current trading prices, PRE is priced at $19.68, while PRENW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas PRENW's P/E ratio is N/A. In terms of profitability, PRE's ROE is -0.36%, compared to PRENW's ROE of -0.36%. Regarding short-term risk, PRE is more volatile compared to PRENW. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check PRENW's competition here
PRE vs SQLLW Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, SQLLW has a market cap of 159.3K. Regarding current trading prices, PRE is priced at $19.68, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, PRE's ROE is -0.36%, compared to SQLLW's ROE of +6.06%. Regarding short-term risk, PRE is less volatile compared to SQLLW. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check SQLLW's competition here
PRE vs TTOO Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, TTOO has a market cap of 5.6K. Regarding current trading prices, PRE is priced at $19.68, while TTOO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas TTOO's P/E ratio is -0.01. In terms of profitability, PRE's ROE is -0.36%, compared to TTOO's ROE of +1.47%. Regarding short-term risk, PRE is less volatile compared to TTOO. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check TTOO's competition here
PRE vs BNGOW Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, PRE is priced at $19.68, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas BNGOW's P/E ratio is N/A. In terms of profitability, PRE's ROE is -0.36%, compared to BNGOW's ROE of -0.56%. Regarding short-term risk, PRE is less volatile compared to BNGOW. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check BNGOW's competition here
PRE vs CHEKZ Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, PRE is priced at $19.68, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, PRE's ROE is -0.36%, compared to CHEKZ's ROE of -2.26%. Regarding short-term risk, PRE is less volatile compared to CHEKZ. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check CHEKZ's competition here
PRE vs MEUSW Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, PRE is priced at $19.68, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas MEUSW's P/E ratio is N/A. In terms of profitability, PRE's ROE is -0.36%, compared to MEUSW's ROE of -7.71%. Regarding short-term risk, PRE is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check MEUSW's competition here
PRE vs OCDX Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, PRE is priced at $19.68, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas OCDX's P/E ratio is -42.28. In terms of profitability, PRE's ROE is -0.36%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, PRE is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check OCDX's competition here
PRE vs PRXL Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, PRE is priced at $19.68, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas PRXL's P/E ratio is N/A. In terms of profitability, PRE's ROE is -0.36%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, PRE is more volatile compared to PRXL. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check PRXL's competition here
PRE vs DHR-PA Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, PRE is priced at $19.68, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, PRE's ROE is -0.36%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, PRE is more volatile compared to DHR-PA. This indicates potentially higher risk in terms of short-term price fluctuations for PRE.Check DHR-PA's competition here
PRE vs NDRAW Comparison April 2026
PRE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRE stands at 276.6M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, PRE is priced at $19.68, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRE currently has a P/E ratio of -5.19, whereas NDRAW's P/E ratio is N/A. In terms of profitability, PRE's ROE is -0.36%, compared to NDRAW's ROE of -4.97%. Regarding short-term risk, PRE is less volatile compared to NDRAW. This indicates potentially lower risk in terms of short-term price fluctuations for PRE.Check NDRAW's competition here